Symbols / KZIA
KZIA Chart
About
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 56.79M |
| Enterprise Value | 4.59B | Income | -20.70M | Sales | 1.83M |
| Book/sh | -3.63 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -638.43 | PEG | — |
| P/S | 31.05 | P/B | -1.38 | P/C | — |
| EV/EBITDA | -345.68 | EV/Sales | 2510.51 | Quick Ratio | 0.32 |
| Current Ratio | 0.35 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -13.39 | EPS next Y | -0.01 | EPS Growth | — |
| Revenue Growth | -27.20% | Earnings | — | ROA | -64.28% |
| ROE | — | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -268.37% | Profit Margin | 0.00% | Shs Outstand | 11.34M |
| Shs Float | 790.75M | Short Float | 0.28% | Short Ratio | 0.11 |
| Short Interest | — | 52W High | 17.40 | 52W Low | 2.86 |
| Beta | 1.78 | Avg Volume | 822.83K | Volume | 105.87K |
| Target Price | $19.22 | Recom | None | Prev Close | $5.14 |
| Price | $5.01 | Change | -2.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.28
Mean price target
2. Current target
$5.32
Latest analyst target
3. DCF / Fair value
$-23.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.32
Low
$18.26
High
$20.29
Mean
$19.28
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-10-02 | main | Maxim Group | Buy → Buy | $20 |
| 2025-07-10 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-06-11 | main | Maxim Group | Buy → Buy | $15 |
| 2025-02-06 | init | Maxim Group | — → Buy | $3 |
| 2024-07-12 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-04-11 | up | HC Wainwright & Co. | Neutral → Buy | $2 |
| 2022-08-02 | down | Maxim Group | Buy → Hold | — |
| 2022-08-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-10-14 | init | Maxim Group | — → Buy | $18 |
| 2021-01-05 | init | HC Wainwright & Co. | — → Buy | $17 |
- Kazia Therapeutics (NASDAQ: KZIA) expects $46.5M net from PIPE to extend cash runway - Stock Titan ue, 02 Dec 2025 08
- KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination - Stocktwits Wed, 19 Nov 2025 08
- New Analyst Forecast: $KZIA Given $18 Price Target - Quiver Quantitative Wed, 28 Jan 2026 08
- What's Going On With Kazia Therapeutics Stock Tuesday? - Kazia Therapeutics (NASDAQ:KZIA) - Benzinga ue, 27 Jan 2026 08
- Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com Fri, 30 Jan 2026 08
- Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline - MSN Mon, 24 Nov 2025 04
- (KZIA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily ue, 10 Feb 2026 04
- KZIA: HC Wainwright & Co. Reiterates Buy Rating, Price Target Ma - GuruFocus Wed, 28 Jan 2026 14
- KZIA Stock News Today: Kazia Therapeutics Soars on Rare Cancer Response as Nasdaq Delisting Risk Looms - TechStock² Wed, 19 Nov 2025 08
- Can KZIA stock rebound after recent weakness - July 2025 Market Mood & Technical Buy Zone Confirmation - mfd.ru Fri, 13 Feb 2026 04
- Breast cancer trial drug leaves no detectable disease in one patient - Stock Titan ue, 27 Jan 2026 08
- Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria ue, 18 Nov 2025 08
- (KZIA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Fri, 30 Jan 2026 02
- What Sparked Kazia Therapeutics' Over 51% After-Hours Surge? - Benzinga Wed, 19 Nov 2025 08
- Experimental cancer drug targets hidden resistance driving metastasis - Stock Titan Fri, 30 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -453.07K | 1.19K | 44.28K | 217.48 |
| TaxRateForCalcs | 0.08 | 0.01 | 0.01 | 0.01 |
| NormalizedEBITDA | -7.46M | -26.71M | -25.66M | -23.55M |
| TotalUnusualItems | -5.83M | 119.00K | 3.39M | 15.00K |
| TotalUnusualItemsExcludingGoodwill | -5.83M | 119.00K | 3.39M | 15.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.70M | -26.78M | -20.46M | -25.01M |
| ReconciledDepreciation | 934.00K | 1.87M | 1.87M | 1.87M |
| EBITDA | -13.28M | -26.59M | -22.28M | -23.53M |
| EBIT | -14.22M | -28.46M | -24.15M | -25.40M |
| NetInterestIncome | 72.00K | 12.00K | 22.00K | 2.00K |
| InterestIncome | 72.00K | 12.00K | 22.00K | 2.00K |
| NormalizedIncome | -15.33M | -26.90M | -23.81M | -25.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.70M | -26.78M | -20.46M | -25.01M |
| TotalExpenses | 14.26M | 30.77M | 24.15M | 25.40M |
| DilutedAverageShares | 527.35K | 368.57K | 264.94K | 235.35K |
| BasicAverageShares | 527.35K | 368.57K | 264.94K | 235.35K |
| DilutedEPS | -50.80 | -56.15 | -93.05 | -35.80 |
| BasicEPS | -50.80 | -56.15 | -93.05 | -35.80 |
| DilutedNIAvailtoComStockholders | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncomeCommonStockholders | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncome | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncomeIncludingNoncontrollingInterests | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncomeContinuousOperations | -20.70M | -26.78M | -20.46M | -25.01M |
| TaxProvision | -1.75M | -271.00K | -271.00K | -368.00K |
| PretaxIncome | -22.45M | -27.05M | -20.74M | -25.38M |
| OtherIncomeExpense | -8.30M | 1.40M | 3.39M | 15.00K |
| OtherNonOperatingIncomeExpenses | -2.48M | 1.28M | 1.00K | |
| SpecialIncomeCharges | -5.83M | 119.00K | 3.39M | 15.00K |
| GainOnSaleOfPPE | 0.00 | |||
| WriteOff | 0.00 | 0.00 | -15.00K | 0.00 |
| ImpairmentOfCapitalAssets | 13.38M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | -7.55M | -119.00K | -3.39M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 72.00K | 12.00K | 22.00K | 2.00K |
| InterestIncomeNonOperating | 72.00K | 12.00K | 22.00K | 2.00K |
| OperatingIncome | -14.22M | -28.46M | -24.15M | -25.40M |
| OperatingExpense | 14.26M | 30.77M | 24.15M | 25.40M |
| OtherOperatingExpenses | -1.79M | -173.00K | -1.00K | -10.00K |
| OtherTaxes | 0.00 | 0.00 | -2.00K | |
| ResearchAndDevelopment | 7.33M | 17.38M | 15.56M | 20.17M |
| SellingGeneralAndAdministration | 8.72M | 13.56M | 8.58M | 5.24M |
| SellingAndMarketingExpense | 0.00 | 0.00 | 127.00K | 0.00 |
| GeneralAndAdministrativeExpense | 8.72M | 13.56M | 8.58M | 5.11M |
| OtherGandA | 8.72M | 13.56M | 8.58M | 5.11M |
| TotalRevenue | 42.00K | 2.31M | 0.00 | 0.00 |
| OperatingRevenue | 42.00K | 2.31M | 0.00 | 0.00 |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 809.42M | 332.85M | 228.03M | 138.76M |
| ShareIssued | 809.42M | 332.85M | 228.03M | 138.76M |
| TotalDebt | 396.00K | 634.00K | 1.80M | 1.84M |
| TangibleBookValue | -9.39M | -25.42M | -5.22M | -864.00K |
| InvestedCapital | -7.91M | -9.38M | 13.85M | 20.12M |
| WorkingCapital | -9.12M | -19.65M | 3.21M | 2.72M |
| NetTangibleAssets | -9.39M | -25.42M | -5.22M | -864.00K |
| CommonStockEquity | -8.30M | -10.02M | 12.05M | 18.27M |
| TotalCapitalization | -8.30M | -10.02M | 12.05M | 18.27M |
| TotalEquityGrossMinorityInterest | -8.30M | -10.02M | 12.05M | 18.27M |
| StockholdersEquity | -8.30M | -10.02M | 12.05M | 18.27M |
| OtherEquityInterest | 464.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 3.10M | 3.48M | 3.68M | 2.41M |
| RetainedEarnings | -134.83M | -115.13M | -89.08M | -68.62M |
| AdditionalPaidInCapital | 380.00K | 0.00 | 0.00 | 0.00 |
| CapitalStock | 123.05M | 101.64M | 97.45M | 84.48M |
| CommonStock | 123.05M | 101.64M | 97.45M | 84.48M |
| TotalLiabilitiesNetMinorityInterest | 14.36M | 31.60M | 16.03M | 17.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 309.00K | 5.80M | 8.47M | 10.89M |
| OtherNonCurrentLiabilities | 3.75M | 6.12M | 8.21M | 10.30M |
| EmployeeBenefits | 37.00K | 35.00K | 59.00K | 117.00K |
| NonCurrentDeferredLiabilities | 272.00K | 2.02M | 2.29M | 2.56M |
| NonCurrentDeferredTaxesLiabilities | 272.00K | 2.02M | 2.29M | 2.56M |
| CurrentLiabilities | 14.05M | 25.80M | 7.57M | 6.73M |
| OtherCurrentLiabilities | 3.15M | 9.73M | 750.00K | 759.00K |
| CurrentDebtAndCapitalLeaseObligation | 396.00K | 634.00K | 1.80M | 1.84M |
| CurrentDebt | 396.00K | 634.00K | 1.80M | 1.84M |
| OtherCurrentBorrowings | 396.00K | 634.00K | 1.80M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 390.00K | 365.00K | 690.00K | 369.00K |
| PayablesAndAccruedExpenses | 10.12M | 15.07M | 4.33M | 3.76M |
| CurrentAccruedExpenses | 4.47M | 10.52M | 3.47M | 2.23M |
| Payables | 5.64M | 4.55M | 857.00K | 1.52M |
| OtherPayable | 2.24M | 3.04M | ||
| AccountsPayable | 5.64M | 4.55M | 857.00K | 1.52M |
| TotalAssets | 6.06M | 21.59M | 28.08M | 35.89M |
| TotalNonCurrentAssets | 1.13M | 15.44M | 17.31M | 26.44M |
| NonCurrentPrepaidAssets | 40.00K | 40.00K | 43.00K | 7.30M |
| GoodwillAndOtherIntangibleAssets | 1.09M | 15.40M | 17.27M | 19.14M |
| OtherIntangibleAssets | 1.09M | 15.40M | 17.27M | 19.14M |
| CurrentAssets | 4.93M | 6.14M | 10.77M | 9.45M |
| OtherCurrentAssets | 1.72M | |||
| PrepaidAssets | 499.00K | 4.36M | 5.43M | 2.04M |
| Receivables | 90.00K | 133.00K | 105.00K | 51.00K |
| OtherReceivables | 90.00K | 133.00K | 104.00K | 51.00K |
| TaxesReceivable | 0.00 | |||
| AccountsReceivable | 0.00 | 1.00K | 0.00 | 84.00K |
| CashCashEquivalentsAndShortTermInvestments | 4.34M | 1.66M | 5.24M | 7.36M |
| CashAndCashEquivalents | 4.34M | 1.66M | 5.24M | 7.36M |
| CashEquivalents | 0.00 | 6.50M | ||
| CashFinancial | 4.34M | 1.66M | 5.24M | 7.36M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -13.28M | -9.58M | -15.16M | -22.76M |
| RepaymentOfDebt | 0.00 | -371.00K | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 776.00K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 14.80M | 5.58M | 12.97M | 3.73M |
| EndCashPosition | 4.34M | 1.66M | 5.24M | 7.36M |
| BeginningCashPosition | 1.66M | 5.24M | 7.36M | 27.59M |
| EffectOfExchangeRateChanges | -16.00K | 12.00K | 64.00K | 1.18M |
| ChangesInCash | 2.70M | -3.60M | -2.18M | -21.40M |
| FinancingCashFlow | 15.98M | 5.99M | 12.97M | 3.73M |
| CashFlowFromContinuingFinancingActivities | 15.98M | 5.99M | 12.97M | 3.73M |
| ProceedsFromStockOptionExercised | 1.18M | 0.00 | 0.00 | |
| NetCommonStockIssuance | 14.80M | 5.58M | 12.97M | 3.73M |
| CommonStockIssuance | 14.80M | 5.58M | 12.97M | 3.73M |
| NetIssuancePaymentsOfDebt | 0.00 | 405.00K | 0.00 | 0.00 |
| NetShortTermDebtIssuance | 0.00 | 405.00K | 0.00 | 0.00 |
| ShortTermDebtPayments | 0.00 | -371.00K | 0.00 | 0.00 |
| ShortTermDebtIssuance | 0.00 | 776.00K | 0.00 | 0.00 |
| InvestingCashFlow | 0.00 | 0.00 | -2.37M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | 0.00 | -2.37M | 0.00 |
| NetOtherInvestingChanges | -2.37M | |||
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| NetBusinessPurchaseAndSale | -2.37M | 0.00 | ||
| PurchaseOfBusiness | -2.37M | 0.00 | ||
| OperatingCashFlow | -13.28M | -9.58M | -15.16M | -22.76M |
| CashFlowFromContinuingOperatingActivities | -13.28M | -9.58M | -15.16M | -22.76M |
| ChangeInWorkingCapital | -3.01M | 10.00M | 4.33M | 862.00K |
| ChangeInOtherWorkingCapital | -1.72M | -620.00K | -7.00K | -167.00K |
| ChangeInOtherCurrentLiabilities | -238.00K | -1.16M | -45.00K | 1.84M |
| ChangeInOtherCurrentAssets | 100.00K | 1.04M | 365.00K | -277.00K |
| ChangeInPayablesAndAccruedExpense | -4.95M | 10.74M | 569.00K | -528.00K |
| ChangeInPayable | -4.95M | 10.74M | 569.00K | -528.00K |
| ChangeInPrepaidAssets | 365.00K | 1.56M | -1.18M | |
| ChangeInReceivables | 3.80M | 5.00K | 3.45M | -7.00K |
| ChangesInAccountReceivables | 3.80M | 5.00K | 3.45M | -6.00K |
| OtherNonCashItems | -5.83M | 6.09M | -2.10M | 152.00K |
| StockBasedCompensation | 653.00K | 533.00K | 1.16M | 1.68M |
| UnrealizedGainLossOnInvestmentSecurities | 982.00K | -1.28M | 0.00 | 0.00 |
| AssetImpairmentCharge | 13.38M | 0.00 | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 934.00K | 1.87M | 1.87M | 1.87M |
| DepreciationAndAmortization | 934.00K | 1.87M | 1.87M | 1.87M |
| AmortizationCashFlow | 934.00K | 1.87M | 1.87M | 1.87M |
| AmortizationOfIntangibles | 934.00K | 1.87M | 1.87M | 1.87M |
| OperatingGainsLosses | 310.00K | -20.00K | 46.00K | -2.15M |
| NetForeignCurrencyExchangeGainLoss | 310.00K | -20.00K | 46.00K | -2.15M |
| NetIncomeFromContinuingOperations | -20.70M | -26.78M | -20.46M | -25.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KZIA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|